Chemistry Reference
In-Depth Information
[4] Hajduk, P. J. and Greer, J., A decade of fragment-based drug design: strategic advances and
lessons learned.
Nat Rev Drug Discov
, 2007,
6
, 211-219.
[5] Zartler, E. R. and Shapiro, M. J., Fragonomics: fragment-based drug discovery.
Curr Opin
Chem Biol
, 2005,
9
, 366-370.
[6] Lepre, C. A.,
et al
., Theory and applications of NMR-based screening in pharmaceutical
research.
Chem Rev
, 2004,
104
, 3641-3676.
[7] Hann, M. M.,
et al
., Molecular complexity and its impact on the probability of finding leads
for drug discovery.
J Chem Inf Comput Sci
, 2001,
41
, 856-864.
[8] Lipinski, C. and Hopkins, A., Navigating chemical space for biology and medicine.
Nature
,
2004,
432
, 855-861.
[9] Andrews, P. R.,
et al
., Functional group contributions to drug-receptor interactions.
J Med
Chem
, 1984,
27
, 1648-1657.
[10] Hopkins, A. L.,
et al
., Ligand efficiency: a useful metric for lead selection.
Drug Discov Today
,
2004,
9
, 430-431.
[11] Lipinski, C. A.,
et al
., Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings.
Adv Drug Deliv Rev
, 1997,
46
,
3-26.
[12] Kuntz, I. D.,
et al
., The maximal affinity of ligands.
Proc Natl Acad Sci USA
, 1999,
96
,
9997-10002.
[13] Abad-Zapatero, C. and Metz, J. T., Ligand efficiency indices as guideposts for drug discovery.
Drug Discov Today
, 2005,
10
, 464-469.
[14] Dalvit, C.,
et al
., NMR-based quality control approach for the identification of false posit-
ives and false negatives in high throughput screening.
Curr Drug Discov Technol
, 2006,
3
,
115-124.
[15] Teague, S. J.,
et al
., The design of leadlike combinatorial libraries.
Angew Chem Int Ed
, 1999,
38
, 3743-3748.
[16] Wenlock, M. C.,
et al
., A comparison of physiochemical property profiles of development and
marketed oral drugs.
J Med Chem
, 2003,
46
, 1250-1256.
[17] Tjernberg, A.,
et al
., Mechanism of action of pyridazine analogues on protein tyrosine
phosphatase 1B (PTP1B).
Bioorg Med Chem Lett
, 2004,
14
, 891-895.
[18] Lundqvist, T., The devil is still in the details - driving early drug discovery forward with
biophysical experimental methods.
Curr Opin Drug Discov Devel
, 2005,
8
, 513-519.
[19] Dalvit, C.,
et al
., A general NMR method for rapid, efficient and reliable biochemical
screening.
J Am Chem Soc
, 2003,
125
, 14620-14625.
[20] Hajduk, P. J.,
et al
., Novel inhibitors of Erm methyltransferases from NMR and parallel
synthesis.
J Med Chem
, 1999,
42
, 3852-3859.
[21] Boehm, H. J.,
et al
., Novel inhibitors of DNAgyrase: 3D structure based biased needle screen-
ing, hit validation by biophysical methods and 3D guided optimization. Apromising alternative
to random screening.
J Med Chem
, 2000,
43
, 2664-2674.
[22] Hajduk, P. J.,
et al
., Identification of novel inhibitors of urokinase via NMR-based screening.
J Med Chem
, 2000,
43
, 3862-3866.
[23] Erlanson, D. A.,
et al
., Site-directed ligand discovery.
Proc Natl Acad Sci USA
, 2000,
97
,
9367-9372.
[24] van Dongen, M. J.,
et al
., Structure-based screening as applied to human FABP
4
, a highly
efficient alternative to HTS for hit generation.
J Am Chem Soc
, 2002,
124
, 11874-11880.
[25] Wendt, M. D.,
et al
., Identification of novel binding interactions in the development of potent,
selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis and SAR of
N
-phenyl amide 6-substitution.
J Med Chem
, 2004,
47
, 303-324.
[26] Gill, A. L.,
et al
., Identification of novel p38alpha MAP kinase inhibitors using fragment-based
lead generation.
J Med Chem
, 2005,
48
, 414-426.
